Jillian B. Thomsen - Aug 15, 2022 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Signature
Mark A. Wilson
Stock symbol
NKTR
Transactions as of
Aug 15, 2022
Transactions value $
-$9,549
Form type
4
Date filed
8/17/2022, 07:40 PM
Previous filing
May 17, 2022
Next filing
Nov 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKTR Common Stock Award $0 +166K +97.08% $0.00 337K Aug 15, 2022 Direct F1, F2
transaction NKTR Common Stock Sale -$9.55K -2.01K -0.6% $4.76* 335K Aug 16, 2022 Direct F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NKTR Common Stock Award $0 +332K $0.00 332K Aug 15, 2022 Common Stock 332K $4.91 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted in connection with a retention program and the individual's recent promotion. This grant is in lieu of Issuer's usual end-of-year annual performance grants. These RSUs vest over three years from the date of grant in substantially equal quarterly installments based on continued service.
F2 This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 6,690 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).
F3 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F4 This transaction was executed in multiple trades at prices ranging from $4.67 to $4.88. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer.
F5 Stock options were granted in connection with a retention program and the individual's recent promotion. These stock options are in lieu of the Issuer's usual end-of-year annual performance grants.
F6 Stock options vest over three years from the date of grant in substantially equal monthly installments based on continued service.